• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.91% Nasdaq Down1.27%

    Karyopharm Therapeutics, Inc. (KPTI)

    13.84 Down 0.30(2.12%) 2:57PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Karyopharm Therapeutics, Inc.
    85 Wells Avenue
    2nd Floor
    Newton, MA 02459
    United States - Map
    Phone: 617-658-0600
    Website: http://www.karyopharm.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:71

    Business Summary 

    Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company’s lead drug candidate, Selinexor, a novel selective inhibitor of nuclear export (SINE) compounds that specifically blocks XPO1 cargo binding is in Phase II clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise Topical SINE compound, which has completed preclinical trial for the treatment of wound healing; KPT-335, an oral SINE compound for viral indications; KPT-350 and related SINE compounds for the treatment of inflammatory and autoimmune indications; PAK4 Inhibitors for the treatment of oncology; and Verdinexor, an oral SINE compound that is in Phase 2b clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is headquartered in in Newton, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Karyopharm Therapeutics, Inc.

    Corporate Governance 
    Karyopharm Therapeutics, Inc.’s ISS Governance QuickScore as of Aug 1, 2015 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Michael G. Kauffman M.D., Ph.D., 52
    Co-Founder, Chief Exec. Officer and Director
    Dr. Sharon Shacham Ph.D., MBA, 45
    Co-Founder, Co-Chairman of Scientific Advisory Board, Pres and Chief Scientific Officer
    Dr. Ronald A. DePinho M.D., 60
    Mr. Justin A. Renz CPA, M.S.T., M.B.A., 43
    Chief Financial Officer, Exec. VP and Treasurer
    Mr. Ran Frenkel RPh., 46
    Exec. VP of Worldwide Devel. Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders